NAGE Niagen Bioscience Inc
Healthcare$3.90+0.00%OpenMarket Cap: $310.2M
As of 2026-05-26
Valuation
View DetailsP/E (TTM)
20.59
PEG
0.20
P/B
3.55
P/S
2.24
EV/EBITDA
17.02
DCF Value
$-1.76
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
8.5%
Net Margin
14.3%
ROE
25.4%
ROA
16.3%
ROIC
11.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $31.5M | $6.3M | $— |
| Q4 null | $33.8M | $4.1M | $— |
| FY null | $129.4M | $17.4M | $— |
| Q3 null | $34.0M | $4.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$10.50
Target (Median)
$10.50
Target Range
$10.00 - $11.00
0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-11Canaccord GenuityBuy
2026-05-05Canaccord GenuityBuy
2026-03-31Canaccord GenuityBuy
2025-11-05HC Wainwright & Co.Buy
2025-08-11Trading Activity
Insider Trades
View AllFried Robert Ndirector, officer: Chief Executive Officer
SellMon Apr 27
Pamir Ozanofficer: Chief Financial Officer
SellTue Feb 24
Lopez Carlos Luisofficer: SVP, General Counsel
SellTue Feb 24
Fried Robert Ndirector, officer: Chief Executive Officer
SellTue Feb 24
Pamir Ozanofficer: Chief Financial Officer
BuyMon Nov 17